Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Robert L. Kortum"'
Autor:
Patricia L. Theard, Amanda J. Linke, Nancy E. Sealover, Brianna R. Daley, Johnny Yang, Katherine Cox, Robert L. Kortum
Publikováno v:
Molecular Oncology, Vol 18, Iss 3, Pp 641-661 (2024)
Son of sevenless 1 and 2 (SOS1 and SOS2) are RAS guanine nucleotide exchange factors (RasGEFs) that mediate physiologic and pathologic receptor tyrosine kinase (RTK)‐dependent RAS activation. Here, we show that SOS2 modulates the threshold of epide
Externí odkaz:
https://doaj.org/article/1c1ff9a6c36d40abb84f70fb414016e7
Autor:
Nancy E. Sealover, Jacob M. Hughes, Patricia L. Theard, Deepan Chatterjee, Amanda J. Linke, Bridget A. Finniff, Brianna R. Daley, Robert E. Lewis, Robert L. Kortum
Publikováno v:
STAR Protocols, Vol 5, Iss 4, Pp 103361- (2024)
Summary: Acquired resistance to oncogene-targeted therapies is the major driver of mortality for patients with cancer. Here, we present a 6-to-16-week assay to model the development of acquired resistance in adherent and suspension cancer cell lines.
Externí odkaz:
https://doaj.org/article/f0666369e1db465b8a5f5a2b715e72c7
Autor:
Stacey Stauffer, Jacob S. Roth, Edjay R. Hernandez, Joshua T. Kowalczyk, Nancy E. Sealover, Katie E. Hebron, Amy James, Kristine A. Isanogle, Lisa A. Riffle, Lilia Ileva, Xiaoling Luo, Jin-Qiu Chen, Noemi Kedei, Robert L. Kortum, Haiyan Lei, Jack F. Shern, Joseph D. Kalen, Elijah F. Edmondson, Matthew D. Hall, Simone Difilippantonio, Carol J. Thiele, Marielle E. Yohe
Publikováno v:
Cancers, Vol 16, Iss 13, p 2320 (2024)
Activating mutations in the RAS/MAPK pathway are observed in relapsed neuroblastoma. Preclinical studies indicate that these tumors have an increased sensitivity to inhibitors of the RAS/MAPK pathway, such as MEK inhibitors. MEK inhibitors do not ind
Externí odkaz:
https://doaj.org/article/6aa231f7d2064697bf39a93b7ac6369e
Autor:
Nancy E. Sealover, Patricia T. Theard, Jacob M. Hughes, Amanda J. Linke, Brianna R. Daley, Robert L. Kortum
Publikováno v:
iScience, Vol 27, Iss 1, Pp 108711- (2024)
Summary: Intrinsic and acquired resistance limit the window of effectiveness for oncogene-targeted cancer therapies. Here, we describe an in situ resistance assay (ISRA) that reliably models acquired resistance to RTK/RAS-pathway-targeted therapies a
Externí odkaz:
https://doaj.org/article/935f01a0ae87470eb58212d48ccf07d4
Autor:
Erin Sheffels, Robert L. Kortum
Publikováno v:
Genes, Vol 12, Iss 5, p 662 (2021)
The RAS family of oncogenes (HRAS, NRAS, and KRAS) are among the most frequently mutated protein families in cancers. RAS-mutated tumors were originally thought to proliferate independently of upstream signaling inputs, but we now know that non-mutat
Externí odkaz:
https://doaj.org/article/7700f23d58654e348f8ddeb99189edc0
Autor:
Katie E. Hebron, Xiaolin Wan, Jacob S. Roth, David J. Liewehr, Nancy E. Sealover, William J.E. Frye, Angela Kim, Stacey Stauffer, Olivia L. Perkins, Wenyue Sun, Kristine A. Isanogle, Christina M. Robinson, Amy James, Parirokh Awasthi, Priya Shankarappa, Xiaoling Luo, Haiyan Lei, Donna Butcher, Roberta Smith, Elijah F. Edmondson, Jin-Qiu Chen, Noemi Kedei, Cody J. Peer, Jack F. Shern, W. Douglas Figg, Lu Chen, Matthew D. Hall, Simone Difilippantonio, Frederic G. Barr, Robert L. Kortum, Robert W. Robey, Angelina V. Vaseva, Javed Khan, Marielle E. Yohe
Publikováno v:
Clinical Cancer Research. 29:472-487
Purpose: PAX-fusion negative rhabdomyosarcoma (FN RMS) is driven by alterations in the RAS/MAP kinase pathway and is partially responsive to MEK inhibition. Overexpression of IGF1R and its ligands is also observed in FN RMS. Preclinical and clinical
Autor:
Patricia L Theard, Erin Sheffels, Nancy E Sealover, Amanda J Linke, David J Pratico, Robert L Kortum
Publikováno v:
eLife, Vol 9 (2020)
Drug treatment of 3D cancer spheroids more accurately reflects in vivo therapeutic responses compared to adherent culture studies. In EGFR-mutated lung adenocarcinoma, EGFR-TKIs show enhanced efficacy in spheroid cultures. Simultaneous inhibition of
Externí odkaz:
https://doaj.org/article/4511fbc1380749d192e9b877015f7dca
Autor:
Marielle E. Yohe, Javed Khan, Angelina V. Vaseva, Robert W. Robey, Robert L. Kortum, Frederic G. Barr, Simone Difilippantonio, Matthew D. Hall, Lu Chen, W. Douglas Figg, Jack F. Shern, Cody J. Peer, Noemi Kedei, Jin-Qiu Chen, Elijah F. Edmondson, Roberta Smith, Donna Butcher, Haiyan Lei, Xiaoling Luo, Priya Shankarappa, Parirokh Awasthi, Amy James, Christina M. Robinson, Kristine A. Isanogle, Wenyue Sun, Olivia L. Perkins, Stacey Stauffer, Angela Kim, William J.E. Frye, Nancy E. Sealover, David J. Liewehr, Jacob S. Roth, Xiaolin Wan, Katie E. Hebron
Pharmacodynamic response to trametinib/ganitumab in xenograft models does not predict tumor shrinkage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d7c566bea37a5d8427b5ace824dcd1e
https://doi.org/10.1158/1078-0432.22488359
https://doi.org/10.1158/1078-0432.22488359
Autor:
Marielle E. Yohe, Javed Khan, Angelina V. Vaseva, Robert W. Robey, Robert L. Kortum, Frederic G. Barr, Simone Difilippantonio, Matthew D. Hall, Lu Chen, W. Douglas Figg, Jack F. Shern, Cody J. Peer, Noemi Kedei, Jin-Qiu Chen, Elijah F. Edmondson, Roberta Smith, Donna Butcher, Haiyan Lei, Xiaoling Luo, Priya Shankarappa, Parirokh Awasthi, Amy James, Christina M. Robinson, Kristine A. Isanogle, Wenyue Sun, Olivia L. Perkins, Stacey Stauffer, Angela Kim, William J.E. Frye, Nancy E. Sealover, David J. Liewehr, Jacob S. Roth, Xiaolin Wan, Katie E. Hebron
Related to Figure 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddd7fae2aafc437f40291da739fe21d2
https://doi.org/10.1158/1078-0432.22488377.v1
https://doi.org/10.1158/1078-0432.22488377.v1
Autor:
Marielle E. Yohe, Javed Khan, Angelina V. Vaseva, Robert W. Robey, Robert L. Kortum, Frederic G. Barr, Simone Difilippantonio, Matthew D. Hall, Lu Chen, W. Douglas Figg, Jack F. Shern, Cody J. Peer, Noemi Kedei, Jin-Qiu Chen, Elijah F. Edmondson, Roberta Smith, Donna Butcher, Haiyan Lei, Xiaoling Luo, Priya Shankarappa, Parirokh Awasthi, Amy James, Christina M. Robinson, Kristine A. Isanogle, Wenyue Sun, Olivia L. Perkins, Stacey Stauffer, Angela Kim, William J.E. Frye, Nancy E. Sealover, David J. Liewehr, Jacob S. Roth, Xiaolin Wan, Katie E. Hebron
Purpose:PAX-fusion negative rhabdomyosarcoma (FN RMS) is driven by alterations in the RAS/MAP kinase pathway and is partially responsive to MEK inhibition. Overexpression of IGF1R and its ligands is also observed in FN RMS. Preclinical and clinical s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92f2495e02f2004856ed709224efafc9
https://doi.org/10.1158/1078-0432.c.6532697.v1
https://doi.org/10.1158/1078-0432.c.6532697.v1